Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Inclusion Criteria: 1. 18 years to 70 years; 2. Had a histologically or cytologically confirmed diagnosis of epithelial ovarian cancer； 3. unfit for radical surgery and had received second-line chemotherapy，the disease still progressed or can not tolerate the chemotherapy; 4. Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1); 5. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2; 6. Had a life expectancy of at least 12 weeks; 7. Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥90g/L, platelets ≥ 80×10\^9/L, neutrophils ≥ 1.5×10\^9/L, total bilirubin within 1.5×the upper limit of normal (ULN), and b) ALT and AST≤2.5×the ULN (If liver metastases, serum creatine ≤ 1.5 x ULN); 8. Had not gastrointestinal diseases that lead to malabsorption or impact Drug absorption; 9. had good compliance; 10. Signed and dated informed consent. Exclusion Criteria: 1. patients who had received anti-vascular therapy; 2. Allergic to any ingredients of Apatinib; 3. Participated in other drug clinical researchers within four weeks; 4. Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.) 5. Severe infection; 6. Patients with serious cardiovascular diseases,such as unstable angina, grade 3-4 heart dysfunction (NYHA Standard), congestive heart failure, poor-controlled arterial hypertension despite standard medical management; 7. Patients who received major surgical operations within 4 weeks before screening; 8. Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening; 9. Past or concurrent with other malignancies, except for cured skin basal cell carcinoma and cervical in situ cancer; 10. Have a history of psychiatric abuse and can not quit or have mental disorders.